Russia Pursues Single-Dose, Light Version of Sputnik V Vaccine
Russian researchers are reportedly seeking approval for a single-dose version of the Sputnik V COVID-19 vaccine and are conducting clinical trials in Russia, the United Arab Emirates and Ghana.
Peer-reviewed interim phase 3 data released last month showed the Sputnik V vaccine demonstrated nearly 92 percent efficacy as a two-dose shot.
The single-shot vaccine is meant as a temporary solution for nations with skyrocketing rates of infections.
The application for approval is reportedly based on smaller phase 1 and 2 clinical trials, and not the phase 3 trials currently under way.